Chime Biologics, Leads Biolabs, and BeiGene Form Strategic Partnership for LAG-3 mAb LBL-007
Wuhan-based Contract Development and Manufacturing Organization (CDMO) Chime Biologics has signed a strategic cooperation agreement...
Sirnaomics Ltd Partners with Edirna Inc. to Advance RNA Editing Therapy
Sirnaomics Ltd (HKG: 2257), a leading company in the field of RNA therapeutics, has announced...
CDE Launches Trial Procedures for Adding Pediatric Information to Drug Inserts
The Center for Drug Evaluation (CDE) has released the “Work Procedures for Adding Children’s Drug...
Sino Biopharmaceutical’s F-star Therapeutics Inks Third Licensing Deal with Takeda for Immunotherapies
Sino Biopharmaceutical Ltd (HKG: 1177) has announced a third licensing agreement between its subsidiary, F-star...
3SBio Inc. Receives NMPA Approval for Nalfurafine Tablets to Treat Hemodialysis-Related Pruritus
China-based 3SBio Inc. (HKG: 1530) has announced receiving marketing approval from the National Medical Products...
Tot Biopharmaceutical and GL-Biotech Collaborate on DisacLink Technology for ADC Advancements
China-based Tot Biopharma International Co., Ltd (HKG: 1875) has announced a strategic partnership with compatriot...
Jiangsu Hengrui Pharmaceuticals Gets NMPA Approval for Esflurbiprofen Patch Clinical Study
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...
Biocytogen Pharmaceuticals Enters Antibody License Agreement with Pheon Therapeutics for ADC Development
China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315) has announced an antibody license agreement with...
Nanjing Kati Medical and Leman Biotech Partner to Advance Immune Metabolism Reprogramming in CAR-T Therapy
Nanjing Kati Medical Technology Co., Ltd, a China-based company, has entered into a partnership with...
Brii Biosciences Expands Collaboration with VBI Vaccines on Hepatitis B Virus Therapies
China-based Brii Biosciences Ltd (HKG: 2137) has announced an expanded license agreement with US firm...
NMPA Launches “Drug Standard Management Measures” to Enhance Drug Quality and Safety
The National Medical Products Administration (NMPA) has released the “Drug Standard Management Measures,” a set...
China’s MofCOM Hosts Symposium with Multinational Corporations, Promises Development Opportunities
This week, China’s Ministry of Commerce (MofCOM) convened a symposium attended by representatives from a...
Genprex Inc. Receives Chinese Patent Protection for Reqorsa Immunogene Therapy
Texas-based gene therapy company Genprex Inc., (NASDAQ: GNPX), has reported receiving a patent protection award...
Moderna Inc. Plans USD 1 Billion Investment in Shanghai for mRNA Vaccine Production
US-based mRNA specialist Moderna Inc. (NASDAQ: MRNA) has revealed further details of its entry into...
CSPC Pharmaceutical Group Receives Marketing Approval for Desvenlafaxine in China
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced receiving marketing approval in China for...
AbbVie’s Rinvoq Receives NMPA Approval for Moderate to Severe Crohn’s Disease Treatment
US pharmaceutical firm AbbVie (NYSE: ABBV) has announced receiving market approval from the National Medical...
Luye Pharma’s Goserelin Acetate Microspheres Approved by NMPA for Prostate Cancer Treatment
Luye Pharma Group (HKG: 2186) has announced that it has received market approval from the...
CDE Releases 72nd Batch of Generic Reference Preparations with New Specifications
The Center for Drug Evaluation (CDE) has released the 72nd batch of chemical generic reference...
Huadong Medicine’s Liraglutide Biosimilar Gains NMPA Approval for Weight Loss Indication
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received additional indication...
Abbisko Therapeutics’ EGFR Inhibitor ABSK112 Clears FDA for Global Phase I NSCLC Study
Shanghai-based biotech firm Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that it has received...